GlobeNewswire

Oxford Immunotec Reports First Quarter 2018 Financial Results

Dela

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced first quarter 2018 financial results.

"Our first quarter results were in line with our expectations, with immigration headwinds and severe winter weather in the U.S., as well as unfavorable order timing in Asia all contemplated in our revenue guidance," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Our strategy and priorities for 2018 are unchanged. We expect to continue our long track record of strong revenue growth in the remaining quarters of 2018, while also advancing the company towards profitability."

By revenue type, total revenues were, in millions:

    Three Months Ended March 31,  
      2018     2017   Percent Change
               
Product   $   7.9   $   8.4     -5 %  
Service       13.5       13.1   2 %  
Total Revenue   $   21.4   $   21.5   -1 %  
               

By indication, total revenues were, in millions:

    Three Months Ended March 31,  
      2018     2017   Percent Change  
               
Tuberculosis   $   18.9   $   18.5   2 %  
Tick-Borne Disease and Other       2.5       3.0   -15 %  
Total Revenue   $   21.4   $   21.5   -1 %  
               

By geography, total revenues were, in millions:

    Three Months Ended March 31,  
            Percent Change  
      2018     2017   As Reported   Constant 
Currency 
(1)
 
                   
United States   $  13.4   $   13.5   -1 %   -1 %  
Europe & ROW     2.3       1.8   24 %   9 %  
Asia       5.7       6.2   -7 %   -9 %  
Total revenue   $   21.4   $   21.5   -1 %   -2 %  
                   

 (1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

First Quarter 2018 Financial Results

Revenue for the first quarter of 2018 was $21.4 million, representing a 1% decrease from first quarter 2017 revenue of $21.5 million. On a constant currency basis, revenue declined 2% versus the prior year period. Tuberculosis revenue for the first quarter of $18.9 million increased 2% over the prior year period. 

2018 first quarter product revenue was $7.9 million, representing a 5% decrease from product revenue of $8.4 million in the first quarter of 2017. The decrease was primarily attributable to lower revenue in Asia due to order timing. Service revenue for the first quarter of 2018 was $13.5 million, up 2% from 2017 first quarter service revenue of $13.1 million. The increase in service revenue was primarily driven by increased tuberculosis revenues in the United States and United Kingdom.

United States revenue was $13.4 million in the first quarter of 2018, representing a 1% decrease from revenue of $13.5 million in the prior year period. The decrease was primarily due to the impact of severe weather and lower sales of blood donor screening kits.

Europe & ROW revenue was $2.3 million in the first quarter of 2018, representing a 24% increase compared to the first quarter of 2017. On a constant currency basis, Europe & ROW increased 9% versus the first quarter of 2017. The increase was driven by strong tuberculosis revenue growth in the U.K. and continental European markets.

Asia revenue was $5.7 million in the first quarter of 2018, representing a decrease of 7% compared to 2017 first quarter revenue of $6.2 million. On a constant currency basis, Asia revenue declined 9% versus the first quarter of 2017. The decline was due to the timing of orders.

Gross profit for the first quarter of 2018 was $10.8 million, a decrease of approximately $0.2 million from gross profit of $11.0 million in the same period of 2017. Gross margin was 50.4%, a decrease of 80 basis points from gross margin of 51.2% in the first quarter of 2017. The first quarter 2018 gross margin performance was impacted by service mix, currency, and infrastructure investments necessary to meet future growth in our clinical tick-borne disease business.

Operating expenses were $20.3 million in the first quarter of 2018, an increase of approximately $2.3 million compared to $18.0 million in the first quarter of 2017. In the first quarter of 2017, we recorded a $2.4 million credit related to the change in fair value of contingent consideration associated with the acquisition of Immunetics, Inc. Excluding this credit, operating expenses in the first quarter of 2018 were essentially flat versus the prior year period.

Net loss for the first quarter of 2018 was $10.3 million, or $0.40 per share, compared to $8.1 million, or $0.36 per share, in the first quarter of 2017. Net loss per share was based on 25,718,910 and 22,533,531 weighted average ordinary shares outstanding for the first quarters of 2018 and 2017, respectively. 

EBITDA for the first quarter of 2018 was $(8.5) million compared to $(6.2) million in the first quarter of 2017. Adjusted EBITDA was $(6.7) million for the first quarter of 2018 compared to $(7.3) million in the same period in 2017. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

In light of the decision to scale down the blood donor screening business, for full year 2018, the Company now expects revenue of between $112 and $115 million, representing 9% - 12% year-over-year growth as reported.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, May 1, 2018 at 8:00 a.m. Eastern Time to discuss its first quarter 2018 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 9793845 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

 

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)

 
        Three months ended March 31,
(in thousands, except share and per share data)     2018       2017  
Revenue                
Product   $   7,935      $   8,386   
Service       13,435          13,119   
Total revenue       21,370          21,505   
Cost of revenue                
Product       2,574          3,245   
Service       8,016          7,252   
Total cost of revenue       10,590          10,497   
Gross profit     10,780        11,008   
Operating expenses:                
Research and development       3,744          3,805   
Sales and marketing       9,405          9,640   
General and administrative       6,928          6,876   
Change in fair value of contingent purchase price consideration       -          (2,357 )
Settlement expense       207      -   
Total operating expenses       20,284          17,964   
Loss from operations       (9,504 )       (6,956 )
Other expense:                
Interest expense, net       (604 )       (823 )
Foreign exchanges losses       (103 )       (106 )
Other expense       (52 )       (140 )
Loss before income taxes       (10,263 )       (8,025 )
Income tax expense       (63 )       (47 )
Net loss   $   (10,326 )   $   (8,072 )
                 
Net loss per ordinary share-basic and diluted   $   (0.40 )   $   (0.36 )
                 
Weighted-average shares used to compute net loss per ordinary share-basic and diluted       25,718,910          22,533,531   
                 

 

Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)

 
        Three months ended March 31,
(in thousands)     2018       2017  
Net loss   $   (10,326 )   $   (8,072 )
Income tax expense       63          47   
Interest expense, net       464          674   
Depreciation and amortization of intangible assets       1,133          1,003   
Accretion and amortization of loan fees       140          149   
EBITDA       (8,526 )       (6,199 )
                 
Reconciling items:                
Share-based compensation expense       1,824          1,326   
Unrealized exchange gains       (159  )       (38 )
Change in fair value of contingent purchase price consideration       -          (2,357 )
Settlement expense       207          -   
Adjusted EBITDA   $   (6,654 )   $   (7,268 )
                 

(1)  EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)
         
    March 31,   December 31,
(in thousands, except share and per share data)     2018       2017  
Assets        
Current assets:        
Cash and cash equivalents   $   77,246      $   90,332   
Accounts receivable, net       16,900          16,981   
Inventory, net       10,909          10,142   
Prepaid expenses and other assets       4,568          3,027   
       
Total current assets       109,623          120,482   
Restricted cash, non-current       200          200   
Property and equipment, net       9,239          9,067   
Goodwill       3,967          3,967   
Other intangible assets, net       7,689          7,849   
Deferred tax asset       2,915          2,486   
Other assets       184          185   
         
Total assets   $   133,817      $   144,236   
         
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $   6,323      $   6,842   
Accrued liabilities       8,564          11,134   
Settlement liability       4,581          4,342   
Deferred income       32          36   
Current portion of loans payable       93          91   
         
Total current liabilities       19,593          22,445   
Long-term portion of loans payable       30,020          29,904   
Settlement liability       4,106          3,894   
Other liabilities       486          364   
         
Total liabilities       54,205          56,607   
         
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at March 31, 2018 and December 31, 2017, and 25,875,358 and 25,661,634 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively       271          269   
Additional paid-in capital       296,363          294,613   
Accumulated deficit       (211,867 )       (201,541 )
Accumulated other comprehensive loss       (5,155 )       (5,712 )
         
Total shareholders' equity       79,612          87,629   
         
Total liabilities and shareholders' equity   $   133,817      $   144,236   
         

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum